| Literature DB >> 33963368 |
R P Vogelsang1, R D Bojesen1,2, E R Hoelmich1, A Orhan1, F Buzquurz1, L Cai1, C Grube1, J A Zahid1, E Allakhverdiiev1,3, H H Raskov1, I Drakos1, N Derian1, P B Ryan4,5, P R Rijnbeek6, I Gögenur1,7.
Abstract
BACKGROUND: Personalized risk assessment provides opportunities for tailoring treatment, optimizing healthcare resources and improving outcome. The aim of this study was to develop a 90-day mortality-risk prediction model for identification of high- and low-risk patients undergoing surgery for colorectal cancer.Entities:
Mesh:
Year: 2021 PMID: 33963368 PMCID: PMC8105588 DOI: 10.1093/bjsopen/zrab023
Source DB: PubMed Journal: BJS Open ISSN: 2474-9842
Baseline characteristics of the study cohort
| Characteristic | Study cohort ( | Missing | Alive 90 days after surgery ( | Deceased within 90 days after surgery ( |
|---|---|---|---|---|
|
| ||||
|
| 15 340 (46.6) | 0 (0) | 14 563 (46.7) | 777 (44.3) |
|
| 70.3(10.5) | 0 | 69.9(10.4) | 79. (8.8) |
|
| 170.83(9.4) | 4741(14.4) | 170.89(9.4) | 169.26(10.0) |
|
| 75.75(16.8) | 4596(14.0) | 75.92(16.8) | 71.61(17.7) |
|
| 5693 (17.3) | |||
| Non-smoker | 10 214 (37.5) | – | 9864 (37.7) | 350 (32.5) |
| Ex-smoker | 11 533 (42.4) | – | 11 078 (42.4) | 455 (42.3) |
| Current smoker | 5487 (20.2) | – | 5215 (19.9) | 272 (25.3) |
|
| 5568 (16.9) | |||
| Consumer, 1–14 drinks/week | 16 176 (59.1) | – | 15 643 (59.5) | 533 (49.1) |
| Consumer, 15–21 drinks/week | 2037 (7.45) | – | 1972 (7.5) | 65 (6.0) |
| Consumer, >21 drinks/week | 1964 (7.2) | – | 1879 (7.2) | 85 (7.8) |
| Non-consumer | 7182 (26.3) | – | 6779 (25.8) | 403 (37.1) |
|
| ||||
|
| 460 (1.4) | |||
| I | 7418 (22.9) | – | 7316 (23.8) | 102 (5.9) |
| II | 18 149 (55.9) | – | 17 496 (56.9) | 653 (38.1) |
| III | 6516 (20.1) | – | 5683 (18.5) | 833 (48.5) |
| IV | 368 (1.1) | – | 245 (0.8) | 123 (7.2) |
| V | 16 (0.0) | – | 11 (0.0) | 5 (0.3) |
|
| 0 (0) | |||
| 0 | 20 756 (63.0) | – | 20 079 (64.4) | 677 (38.6) |
| 1-2 | 9124 (27.7) | – | 8438 (27.1) | 686 (39.1) |
| ≥3 | 3047 (9.3) | – | 2656 (8.5) | 391 (22.3) |
|
| 0 (0) | |||
| Chronic obstructive lung disease | 2619 (8.0) | – | 2314 (7.4) | 305 (17.4) |
| Dementia | 296 (0.9) | – | 230 (0.7) | 66 (3.8) |
| Hemiplegia | 52 (0.2) | – | 44 (0.1) | 8 (0.5) |
| Cerebrovascular disease | 2576 (7.8) | – | 2276 (7.3) | 300 (17.1) |
| Peripheral vascular disease | 1465 (4.5) | – | 1297 (4.2) | 168 (9.6) |
| Heart failure | 1424 (4.3) | – | 1214 (3.9) | 210 (12.0) |
| Myocardial infarction | 1150 (3.5) | – | 1030 (3.3) | 120 (6.8) |
| Secondary malignant disease | 373 (1.1) | – | 322 (1.0) | 51 (2.9) |
| Widespread metastatic malignant disease | 589 (1.8) | – | 533 (1.7) | 56 (3.2) |
| Liver disease, mild | 224 (0.7) | – | 196 (0.6) | 28 (1.6) |
| Liver disease, moderate to severe | 63 (0.2) | – | 48 (0.2) | 15 (0.9) |
| Diabetes mellitus without complications | 2733 (8.3) | – | 2513 (8.1) | 220 (12.5) |
| Diabetes mellitus with complications | 1195 (3.6) | – | 1088 (3.5) | 107 (6.1) |
| Renal insufficiency | 702 (2.1) | – | 581 (1.9) | 121 (6.9) |
| Peptic ulcer | 1012 (3.1) | – | 902 (2.9) | 110 (6.3) |
| Connective tissue disorder | 824 (2.5) | – | 759 (2.4) | 65 (3.7) |
|
| ||||
|
| 5 (0.0) | |||
| Emergency | 2810 (8.5) | – | 2321 (7.5) | 489 (27.9) |
| Elective | 30 112 (91.5) | – | 28 847 (92.6) | 1265 (72.1) |
|
| 0 (0) | |||
| Laparotomy | 15 299 (46.5) | – | 14 070 (45.1) | 1229 (70.1) |
| Laparoscopy | 16 732 (50.8) | – | 16 227 (52.1) | 505 (28.8) |
| TaTME | 106 (0.3) | – | 103 (0.3) | 3 (0.2) |
| Robotic-assisted surgery | 821 (2.5) | – | 802 (2.6) | 19 (1.1) |
|
| 2068 (6.3) | 218 (0.7) | 1966 (6.4) | 102 (5.8) |
|
| 100 (50–300)† | 892 (2.7) | 100 (50–300)† | 250 (100–600)† |
|
| 5107 (15.6) | 110 (0.3) | 4424 (14.2) | 683 (39.1) |
|
| 1254 (6.2) | 12 828 (39.0) | 1134 (5.9) | 120 (13.9) |
|
| ||||
|
| 0 (0) | |||
| Colon | 22 140 (67.2) | – | 20 769 (66.6) | 1371 (78.2) |
| Rectum | 10 787 (32.8) | – | 10 404 (33.4) | 383 (21.8) |
|
| 1675 (5.1) | 56 (0.2) | 1447 (4.7) | 228 (13.0) |
|
| ||||
|
| 0 (0) | |||
| Chemoradiationtherapy | 2545 (7.7) | – | 2497 (8.0) | 48 (2.7) |
| Chemotherapy | 2854 (8.7) | – | 2772 (8.9) | 82 (4.7) |
| Radiotherapy | 2460 (7.5) | – | 2408 (7.7) | 52 (3.0) |
|
| 13 002 (39.5) | |||
| SEMS | 1195 (6.0) | – | 1133 (5.9) | 62 (7.7) |
| Damage-control surgery‡‡ | 3 (0.0) | – | 0 (0) | 3 (0.4) |
| Preoperative MDT assessment§§ | 11 957 (61.4) | 13 449 (40.8) | 11 599 (62.1) | 358 (45.7) |
Values in parentheses are percentages, except where indicated otherwise. *Values are mean(s.d.); †values are median (i.q.r.). ‡Non-smoker, never smoked tobacco; ex-smoker, smoking cessation for ≥8 weeks before surgery; current smoker, currently smoking. §Diagnoses of co-morbidity registered up to 10 years before colorectal cancer diagnosis. ¶Conversion from minimally invasive surgery to open surgery. Transfusion of any blood product during surgery. **Any iatrogenic injury during surgery to undefined anatomical structure, urinary bladder, the duodenum, the gallbladder, the colon, the liver, the spleen, the pancreas, the sacral nerves, the small intestine, the ureter, the urethra, the vagina or the ventricle. ††Rectal cancer, tumours located within 15 cm of the anal verge; colon cancer, tumours located more than 15 cm from the anal verge. ‡‡. §§Multidisciplinary team (MDT) was formally registered since 1 January 2010 (quality control indicator since 1 January 2014). TaTME, transanal total mesorectal excision; SEMS, self-expanding metal stent. Damage Control Surgery: Two-stage surgical procedure due to acute presentation.
Model performance characteristics: identification of high-risk patients at various model thresholds
| Model risk threshold | Proportion of the patients flagged as high-risk by the model (%) | Sensitivity | Specificity | Risk of 90-day mortality (%)* | Relative risk compared with the population | |
|---|---|---|---|---|---|---|
|
| 0.6 | 7.1 | 99.7 | 60.8 | 11.4 | |
|
| 0.9 | 10.0 | 99.6 | 57.9 | 10.9 | |
|
| 1.3 | 13.5 | 99.3 | 53.6 | 10.1 | |
|
| 2.0 | 17.6 | 98.9 | 47.8 | 9.0 | |
|
| 2.8 | 23.5 | 98.4 | 44.8 | 8.4 | |
|
| 3.8 | 29.0 | 97.6 | 40.7 | 7.7 | |
|
| 5.5 | 36.7 | 96.3 | 35.7 | 6.7 | |
|
| 8.3 | 45.0 | 93.7 | 28.7 | 5.4 | |
|
| 14.0 | 60.3 | 88.6 | 23.0 | 4.3 | |
|
| 28.1 | 79.5 | 79.5 | 15.0 | 2.8 | |
|
| 48.5 | 92.2 | 53.9 | 10.1 | 1.9 | |
|
| 79.1 | 98.6 | 22.0 | 6.6 | 1.2 | |
|
| 95.8 | 99.8 | 4.4 | 5.5 | 1.0 | |
Model risk threshold: continuous model coefficient scale ranging from 0.0–1.0. * Positive predictive value. Classification of high-risk patients with an above-average risk of 90-day mortality according to specific model risk threshold settings. The average population risk of 90-day mortality after colorectal cancer surgery was 5.3%.
Model performance characteristics: identification of low-risk patients at various model thresholds
| Model risk threshold | Proportion of patients flagged as low-risk by the model (%) | Specificity | Sensitivity | Risk of 90-day mortality (per cent)* | Relative risk compared with the population |
|---|---|---|---|---|---|
|
| 99.4 | 99.7 | 7.1 | 5.0 | 0.9 |
|
| 99.1 | 99.6 | 10.0 | 4.8 | 0.9 |
|
| 98.7 | 99.3 | 13.5 | 4.7 | 0.9 |
|
| 98.0 | 98.9 | 17.6 | 4.5 | 0.9 |
|
| 97.2 | 98.4 | 23.5 | 4.2 | 0.8 |
|
| 96.2 | 97.6 | 29.0 | 3.9 | 0.7 |
|
| 94.5 | 96.3 | 36.7 | 3.6 | 0.7 |
|
| 91.6 | 93.7 | 45.0 | 3.2 | 0.6 |
|
| 86.0 | 88.6 | 60.3 | 2.5 | 0.5 |
|
| 71.9 | 79.5 | 79.5 | 1.5 | 0.3 |
|
| 51.5 | 53.9 | 92.2 | 0.8 | 0.2 |
|
| 20.9 | 22.0 | 98.6 | 0.3 | 0.1 |
|
| 4.2 | 4.4 | 99.8 | 0.3 | 0.1 |
Model risk threshold: continuous model coefficient scale ranging from 0.0–1.0. *Negative predictive value. Classification of low-risk patients with a below-average risk of 90-day mortality according to specific model risk threshold settings. The average population risk of 90-day mortality after colorectal cancer surgery was 5.3%.